Global Alzheimer’s Platform Foundation® (GAP) Condemns CMS Preliminary Coverage Decision on First Disease Modifying Drug for Alzheimer’s as Repudiation of President’s Promise to Advance Treatments for Alzheimer’s for all Americans

GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]

Read More…

Global Alzheimer’s Platform Foundation® Applauds Biogen for Reducing Cost of ADUHELM

GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the […]

Read More…

Atlanta Metro Communities Gain Access to Renowned Alzheimer’s Research Network Through Local Clinical Trial Site

iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – peterbuonanno@rational360.com – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta […]

Read More…

Orlando Seniors Gain Access to Innovative Alzheimer’s Clinical Trial

Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer’s Research Contact: Peter Buonanno – peterbuonanno@rational360.com – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites […]

Read More…

Global Alzheimer’s Platform Foundation (GAP) Taps Leading International Clinical Trial Expert for Senior Advisor Role

Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]

Read More…

To Beat Alzheimer’s, Tampa Seniors From Underserved Communities can get Involved in Clinical Trials

GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]

Read More…

Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) to Partner with the Global Alzheimer’s Platform Foundation® (GAP) and Other Industry Leaders on Breakthrough Alzheimer’s Study

Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]

Read More…

Statement: Global Alzheimer’s Platform Foundation Praises FDA for Aducanumab Approval

Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]

Read More…

Bio-Hermes Clinical Trial Launches to Compare Biomarker Tests; Seeks Rapid, Less Expensive Diagnostics for Alzheimer’s Disease

Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]

Read More…

Inland Northwest Research Screens First Patient Worldwide for Study of Investigational Parkinson’s Disease Drug

GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]

Read More…